Related content

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer

By  

Cancer Medicine, Vol. 2045-7634, Iss. 10, 2015-10 ,pp. : 1505-1513

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer

By Kambe Mariko   Kikuchi Hiroaki   Gamo Makio   Yoshioka Takashi   Ohashi Yasuo   Kanamaru Ryunosuke  

International Journal of Clinical Oncology, Vol. 17, Iss. 2, 2012-04 ,pp. : 150-154

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer

By Alonso V.   Escudero P.   Zorrilla M.   Isla M.D.   Herrero A.   Mayordomo J.I.   Martinez-Trufero J.   Saenz A.   Tres A.   Anton A.  

European Journal of Cancer, Vol. 37, Iss. 18, 2001-12 ,pp. : 2385-2391

Elsevier

Access to resources Recommend Favorite

Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer

By Goto Ayumu   Yamada Yasuhide   Hosokawa Ayumu   Ura Takashi   Arai Tatsuhiro   Hamaguchi Tetsuya   Muro Kei   Shimada Yasuhiro   Shirao Kuniaki  

International Journal of Clinical Oncology, Vol. 9, Iss. 5, 2004-10 ,pp. : 364-368

Springer Publishing Company

Access to resources Recommend Favorite

Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer

By Park Sook   Hong Yong   Lim Hyeong-Seok   Seong Moon-Woo   Kong Sun-Young   Kim Sun   Park Young-Iee   Jung Kyung  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 953-964

Springer Publishing Company

Access to resources Recommend Favorite